TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00776841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days
Study: NCT03920527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole 400 mg
Description: Duration of itraconazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole 400 mg
Description: Duration of itraconazole
Study: NCT02729545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tung's acupuncture
Description: The study took Tung's acupoints as main acupuncture points, which were Fuke, Huanchao, Tianhuang, Renhuang, as well as the traditional acupoints Guanyuan (CV4) and Zigong (EX-CA1).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyproterone acetate/ethinylestradiol (CPA/EE)
Description: Cyproterone acetate/ethinylestradiol (CPA/EE) contains 2mg cyproterone acetate (an anti-androgenic progestin) and 0.035mg ethinylestradiol (CPA/EE). The pills were administered for 21 days consecutively. The patients then stopped taking the pills for seven days and, on the eighth day, continued to take the pills again for three menstrual cycles (28 day cycles).
Study: NCT00379925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity and Dietary Health Promotion Program
Description: Churches within the intervention group will receive a committee training and church cook training designed to teach them how to do a self-assessment of current practices and develop a plan for their program. The intervention is based on the structural model of health behavior and targets opportunities, mass media (within the church), guidelines and policies, and church environment. Intervention churches also receive monthly intervention mailings to support intervention implementation.
Study: NCT00664417

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent subvirion H5N1 influenza vaccine
Description: 0.5 mL, IM, 2 injections, Formulation 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent subvirion H5N1 influenza vaccine
Description: 0.5 mL, IM, 2 injections, Formulation 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent subvirion H5N1 influenza vaccine
Description: 0.5 mL, IM, 2 injections, Formulation 3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent subvirion H5N1 influenza vaccine
Description: 0.5 mL, IM, 2 injections, Formulation 4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent subvirion H5N1 influenza vaccine
Description: 0.5 mL, IM, 2 injections, Formulation 5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent subvirion H5N1 influenza vaccine
Description: 0.5 mL, IM, 2 injections, Formulation 6

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monovalent subvirion H5N1 influenza vaccine
Description: 0.5 mL, IM, 2 injections, Comparator 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monovalent subvirion H5N1 influenza vaccine
Description: 0.5 mL, IM, 2 injections, Comparator 2

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline
Description: 0.5 mL, IM, 2 injections
Study: NCT02364414

Intervention type: DEVICE
Group type: OTHER
Intervention: 3Shape TRIOS (R)
Description: Direct intra-oral scan of teeth and dentition
Study: NCT01929837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-fied navigated rTMS
Description: 1 hz on the superior temporal gyrus contralateral/left side with E-field navigated rTMS (Nexstim) targeted at the tonotopic representation area of the main frequency content of tinnitus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-navigated rTMS
Description: 1 hz on the superior temporal gyrus contralateral/left side with non-navigated rTMS according to external landmarks (between T3/T4 and P3/P4 EEG-electrode locations)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham E-field navigated rTMS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navigated rTMS
Description: 1 hz on the left superior temporal gyrus with (MRI) navigated rTMS (Visor)
Study: NCT01186744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 10 mg of CP-690,550 oral BID or placebo oral BID, as appropriate based on treatment withdrawal/retreatment design

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 10 mg oral BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 5 mg of CP-690,550 oral BID or Placebo oral BID, as appropriate based on treatment withdrawal/retreatment design

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 5 mg oral BID
Study: NCT00776841

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aramchol
Description: Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days
Study: NCT03820128

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early diet intervention
Description: Participant's diet includes several low-fiber and low-fat commonly available meals and products. Patients will choose what they want to eat with no amount or calories restriction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early diet intervention
Description: Participant's diet includes several low-fiber and low-fat commonly available meals and products. Patients will choose what they want to eat with no amount or calories restriction.
Study: NCT01059838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sentence recognition
Description: testing the ability for sentence recognition in quiet and in noise.
Study: NCT01577212

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Individualized dose escalation
Description: Individualized dose escalation on the basis of the maximally tolerable dose to organs at risk - lung, esophagus, spinal cord, heart, brachial plexus
Study: NCT00397462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: calf muscle pump stimulation
Description: Micromechanical stimulation of the postural reflex arc to activate the soleus muscle to enhance lower limb fluid return to the heart
Study: NCT02107807

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novartis Investigational H5N1 vaccine
Description: 2 doses of 0.5 ml, 3 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novartis Investigational H5N1 vaccine
Description: 2 doses of 0.5 ml, 3 weeks apart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novartis Seasonal Influenza Vaccine
Description: 2 doses of 0.5 ml, 3 weeks apart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novartis Seasonal Influenza Vaccine
Description: 2 doses of 0.5 ml, 3 weeks apart
Study: NCT00604734

Intervention type: DEVICE
Group type: OTHER
Intervention: ReCap Total Hip Resurfacing System
Description: This is a hip resurfacing system.
Study: NCT00686231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin 15mg
Description: 15mg Nitroglycerin applied topically to one wrist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin 30mg
Description: 30mg Nitroglycerin applied topically to one wrist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin 30mg
Description: 30mg Nitroglycerin applied topically to one wrist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin 30mg
Description: 30mg Nitroglycerin applied topically to one wrist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 20mg
Description: 20mg Lidocaine applied topically to one wrist in combination with nitroglycerin or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 40mg
Description: 40mg Lidocaine applied topically to one wrist in combination with nitroglycerin or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Topical skin moisturizing cream with same appearance as active agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Topical skin moisturizing cream with same appearance as active agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Topical skin moisturizing cream with same appearance as active agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Topical skin moisturizing cream with same appearance as active agent
Study: NCT03787849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% for anesthesia induction. After induction and peripheral vein puncture, the anesthesia will be maintained only with sevoflurane 3% until completion of the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% until lost of conscience and peripheral vein puncture. After that, sevoflurane will be turned off and its clearance will be analyzed through gas analyzer monitor. From here, anesthesia will be maintained as total venous with continuous propofol infusion 100 mcg.kg.min-1 until completion of the procedure.
Study: NCT02127008

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection of epidural fat
Description: During surgical procedure, the epidural fat with pituitary forcep and rongeur was resected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No resection of epidural fat
Description: During surgical procedure, the epidural fat with pituitary forcep and rongeur was not resected.
Study: NCT01592513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS monitor
Description: BIS is a monitor of anesthetic depth approved by the FDA. It incorporates time-domain, frequency-domain and bi-spectral analysis of the EEG. This analysis is displayed as a dimensionless number between zero (deep anesthesia) and 100 (awake).~BIS values between 80-90 represent values corresponding to light/moderate sedation.~BIS is a valuable tool for assessing the depth of sedation and guiding the administration of sedative drugs.
Study: NCT01119261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing algorithm
Description: Loading and monitoring dose according to genotype-guided dosing algorithm
Study: NCT01022177

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: acupuncture of the eye in traditional chinese schematics

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: acupuncture of the eye in traditional chinese schematics
Study: NCT00886873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Study: NCT00606996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group interpersonal psychotherapy (IPT-G)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation on co-occurring disorders (PSYCHOED)
Study: NCT00530088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: porfimer sodium
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photdynamic Therapy (PDT)
Study: NCT03684473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mindfulness-Based CBT & Trauma-Informed Yoga Intervention
Description: 8 Weekly Online modules consisting of one weekly video of yoga postures combined with breath awareness and daily guided meditation audios, and a breath technique manual form the foundation of the intervention. The trauma-informed component of the program uses specific language, movement cues, teacher qualities, and physical assists. The yoga intervention will emphasize full choice and control of the participant through invitational language such as, when you are ready, if you like before each body posture cue. Based on trauma-informed yoga best practices, a predictable foundation of yoga postures (with variations) will be followed in a consistent order each session to allow participants to anchor to the series.
Study: NCT03039517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACTitouch
Description: The device is applied to the lower leg (calf, ankle, and foot) and consists of an under-sock worn against the skin, a compression sleeve containing 4 inflatable chambers and a controller unit. The controller provides the airflow to inflate the chambers and monitors and adjusts the chamber pressure to maintain the intended treatment pressures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression garments (stockings)
Description: Compression garments (stockings) now serve as the generally recommended standard of care for patients post DVT and will be utilized as the control compression method in this study. Compression garments utilized in this study will be below the knee style with a pressure range of 30-40 mmHg. If a patient does not have compression garments as indicated, these stockings will be provided.
Study: NCT01119261

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-genotype-guided dosing algorithm
Description: Loading and monitoring dose according to non-genotype-guided dosing algorithm
Study: NCT02522897

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Study: NCT01856140

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection
Study: NCT02800044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearing a non-invasive glucose sensor
Description: Glucose readings will be obtained from both a glucometer (fingerstick readings) and from the non-invasive glucose sensor at the following four timepoints: fasting, 1.5 to 2 hours after consuming a meal, and before and after 15-30 minutes of moderate exercise on a stationary bicycle.
Study: NCT04498897

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vortioxetine
Description: * Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~* First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~* Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acamprosate
Description: * Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~* First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~* Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acamprosate
Description: * Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~* First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~* Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate
Study: NCT03732092

Intervention type: DIAGNOSTIC_TEST
Intervention: Coma Recovery Scale-Revised
Description: Patients with disorders of consciousness were assessed by Coma Recovery Scale-Revised (CRS-R). In addition, we selected three stimuli: 1) 1-octene-3-ol, 2) pyridine, 3) water. We presented these three stimuli in front of the patients nose for 3 seconds.
Study: NCT03258476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine Extended Release
Description: Intuniv (guanfacine) is a prescription medicine used to treat attention deficit hyperactivity disorder (ADHD) in children who are at least 6 years old. An open-label trail of guanfacine extended release (GXR 1-4 mg/daily; Intuniv™) suggested benefits in improving behavioral and emotional regulation in children and adolescents with symptoms of traumatic stress. However, to date no controlled clinical trial has been completed assessing the effects of GXR on traumatic stress symptoms in youths

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Skills Therapy
Description: Mindfulness is a therapy for anxiety and stress. Mindfulness forms of therapy involve regulation of attention, maintaining it in immediate experience, regardless of the valence and desirability of the experience. To reduce anxiety, Mindfulness encourages observing and accepting anxiety-related thoughts

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Skills Therapy
Description: Mindfulness is a therapy for anxiety and stress. Mindfulness forms of therapy involve regulation of attention, maintaining it in immediate experience, regardless of the valence and desirability of the experience. To reduce anxiety, Mindfulness encourages observing and accepting anxiety-related thoughts

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule
Study: NCT04795505

Intervention type: BEHAVIORAL
Intervention: Intervention
Description: The subsequent visit was through WeChat-based online consultations. Follow-up, assessments and feedback were done at each visit. After follow-up, medication adherence and risk factor modification status were assessed, then individualized feedback, encouragement and recommendations were provided.

Intervention type: BEHAVIORAL
Intervention: Control
Description: The subsequent visit was through an offline outpatient clinic at 4 different community hospitals. Participants in this group received standard outpatient cardiology follow-up with formal cardiac rehabilitation and secondary prevention
Study: NCT04135131

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pilates mat exercises and home exercises
Description: Patients with low back pain were randomized into pilates (group 1) or home exercise group (group 2) 3 times/week for 8 weeks. Pilates mat exercise program comprised three sessions a week for 8 weeks (Monday, Wednesday, and Friday), with each session being scheduled for 1 h (5-min warm-up, 50-min exercise, and 5-min cooling) and each set comprising 10 repetitions. The home exercise program included the pelvic tilt in the supine position, hamstring stretch, hip flexors and lumbar extensor stretch, bridge, strengthening the abdominal muscles, cat/camel exercises in the crawl position, leaning on the forearms in the prone position, strengthening the back extensors, and crossed-arms/legs lift exercises.
Study: NCT03380429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RELVAR/BREO
Description: RELVAR/BREO will be available at doses of 100/25 micrograms (µg) and 200/25 µg to be administered via ELLIPTA DPI. Subjects will be administered one inhalation of RELVAR/BREO once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RELVAR/BREO
Description: RELVAR/BREO will be available at doses of 100/25 micrograms (µg) and 200/25 µg to be administered via ELLIPTA DPI. Subjects will be administered one inhalation of RELVAR/BREO once daily.
Study: NCT05734235

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: One Vitamin E tablet daily for 8 days.
Study: NCT03380429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RELVAR/BREO
Description: RELVAR/BREO will be available at doses of 100/25 micrograms (µg) and 200/25 µg to be administered via ELLIPTA DPI. Subjects will be administered one inhalation of RELVAR/BREO once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RELVAR/BREO
Description: RELVAR/BREO will be available at doses of 100/25 micrograms (µg) and 200/25 µg to be administered via ELLIPTA DPI. Subjects will be administered one inhalation of RELVAR/BREO once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RELVAR/BREO
Description: RELVAR/BREO will be available at doses of 100/25 micrograms (µg) and 200/25 µg to be administered via ELLIPTA DPI. Subjects will be administered one inhalation of RELVAR/BREO once daily.